Trial Profile

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Merkel cell carcinoma
Focus Therapeutic Use
Acronyms STAMP

Most Recent Events

22 May 2026 According to a Parker Institute for Cancer Immunotherapy media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29-June 2.
08 Sep 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
08 Sep 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com